•Lantheus reported global revenue of $389.9 million in the third quarter of 2026, up 1.5% year over year.
•Adjusted diluted earnings per share rose to $1.68, while GAAP earnings per share fell to $0.33 in the third quarter of 2026.
•The Curium agreement announced on August 3, 2026, provides for $102.50 per share in cash and contingent value rights that could add up to $12 per share through 2030.
•Rani Therapeutics’ third-quarter net loss was $8.806 million, compared with $7.914 million a year earlier.
•Basic and diluted loss per share was $0.04 in the third quarter, compared with $0.12 in the third quarter of 2025.
•Cash, cash equivalents and marketable securities totaled $45.3 million on September 30, compared with $53.4 million on June 30; the company expects to fund operations through at least the end of 2027.
•Revenue was $18.6 million in the third quarter, up 13% year over year.
•The company posted a net loss of $66.3 million and diluted loss per share of $0.41; about 90% of the loss was tied to accounting expenses and charges.
•Average tokenized assets were $5.0 billion, up 39% year over year.
